NOTA: Las memorias de esta Bienal han sido seleccionadas para ser publicadas en un número especial de una de las revistas internacionales más relevantes y de mayor prestigio en el área.
La 3ra Bienal “La Hormona de Crecimiento" organizada por la Universidad San Francisco de Quito (USFQ), contará con los más importantes investigadores internacionales, expertos en su área de investigación, con quienes en esta ocasión se va a implementar un modelo educativo diferente a lo que usualmente se ofrece en todos los eventos. Previo a la charla magistral de cada uno de los ponentes, se va a presentar por parte de un docente de la USFQ una breve introducción o un caso clínico. De esta forma, en cada una de las sesiones, va a generarse una interesante discusión, que va a permitir al experto internacional trasmitir su conocimiento de una forma ajustada a situaciones reales. Por otro lado, el contenido propuesto va a ir desde la más básico y molecular hasta lo clínico y práctico. Es un evento que sin lugar a duda llenará las expectativas de cada uno de los asistentes.
Equipo Organizador
3ra Bienal “La Hormona de Crecimiento”
Ponentes
BACKELJAUW, PHILIPPE
Fellowship Program Director, Division of Endocrinology
Clinical Director, Cincinnati Growth Center
Director, Turner Syndrome Center of Cincinnati
Professor, UC Department of Pediatrics
Cincinnati, Ohio - USA
BERGADA, IGNACIO
Médico Pediatra Endocrinólogo
Jefe – División de Endocrinología
Hospital de Niños Ricardo Gutiérrez
Investigador del Consejo de Investigación en Salud del Gobierno de la Ciudad de Buenos Aires.
Buenos Aires, Argentina
BRIGHT, GEORGE
George is a pediatric endocrinologist with over 35 years experience in clinical care and clinical research. He completed training in Endocrinology at the University of Virginia; and his early research efforts included the treatment of growth problems with pituitary-derived human growth hormone. After 20 years in clinical care, in 1999 he joined the biopharmaceutical industry and has focused primarily on the design, conduct and interpretation of Phase 1, 2 and 3 trials of recombinant human growth hormone (rhGH), recombinant human insulin-like growth factor-1 (rhIGF-I), combination rhGH and rhIGF-I and now at Versartis, a novel long-acting rhGH fusion protein (VRS-317). While Growth Hormone Clinical Research Director for Novo Nordisk Pharmaceuticals (Princeton), he led efforts to evaluate alternative dosing regimens and treatment groups for rhGH. While at Tercica, he led the clinical efforts with rhIGF-I, culminating in FDA and EMA approvals in children with severe primary IGF-I deficiency. George is board certified in Pediatrics and Pediatric Endocrinology.
CANEPA, MARCO
Assistant Professor of Cardiology
Cardiology Unit, Department of Internal Medicine, University of Genova
Ospedale Policlinico San Martino
Genova, Italy
FRYSTYK, JAN
Professor, dr. med.
Department of Clinical Medicine - The Department of Endocrinology and Diabetes
Department of Clinical Medicine - Medical Research Laboratory
Aarhus University Hospital
Aarhus - Denmark
GREELEY, SIRI
Assistant Professor of Pediatrics and Medicine
Section of Pediatric and Adult Endocrinology, Diabetes and Metabolism
Chicago Center for Diabetes Translation Research
The University of Chicago
Chicago, IL - USA
HOFFMAN, ANDREW
Professor and Senior Vice Chair for Academic Affairs
Department of Medicine
Stanford University
Chief, Endocrinology
VA Palo Alto Health Care System
Stanford, CA - USA
VIVIAN HWA
Vivian Hwa Ph.D Associate Professor of Pediatrics, Division of Endocrinology Basic Research Director, The Cincinnati Center for Growth Disorders Cincinnati Children's Hospital Medical Center.
Vivian Hwa, Ph.D, received her B.S. (Honors) from the University of Sydney, Sydney, Australia and earned her Ph.D in Microbiology from the University of Illinois, Champaign- Urbana. After a post-doctoral fellowship in Microbiology, she switched to Endocrinology and joined the laboratory of Dr Ron G Rosenfeld, then Chair of Pediatrics at Oregon Health Sciences University, Portland, Oregon. Their subsequent seminal identification of the first human mutation in the STAT5B gene launched a long-timed collaboration and interest investigating the molecular basis of severely short statured children who were unresponsive to growth hormone. In addition to STAT5B, mutations identified along the GH-IGF-I axis have led to re-assessment of the human GH receptor (GHR) functional properties, and demonstrations that hypomorphic IGF1R (IGF-1 receptor) expression/functions in humans confer growth retardation starting in utero. Recent application of exome sequence analysis for some unresolved cases have revealed molecular defects beyond the GH-IGF-I axis, including mutations in genes involved in fundamental cellular processes such as centrosomal functions, the cell cycle, DNA repair. Dr Hwa recently joined Cincinnati Children’s Hospital Medical Center to head the basic research unit of the new Cincinnati Center for Growth Disorders.
JOHN J. KOPCHICK, PH.D
Director of the Growth, Diabetes and Obesity Section, Edison Biotechnology
Institute, Konneker Research Laboratories, Ohio University
Goll Ohio Professor of Molecular and Cellular Biology, Biological Science
Department Sciences, Ohio University, Irvine Hall, Athens, OH
VALTER LONGO, PH.D
Edna M. Jones Professor of Gerontology Professor of Biological Sciences,
Davis School of Gerontology University of Southern California
MISRA, MADHUSMITA
Professor of Pediatrics at Harvard Medical School,
Chief of the Division of Pediatric Endocrinology at MassGeneral Hospital for Children
Director of the Pediatric Endocrine-Sports Endocrine-Neuroendocrine Laboratory at Massachusetts General Hospital
Boston, MA - USA
RADOVICK, SALLY
Professor, Department of Pediatrics
Senior Associate Dean for Clinical and Translational Research
Robert Wood Johnson Medical School
Chancellor’s Scholar, Rutgers Biomedical and Health Sciences
Rutgers, The State University of New Jersey - USA
More information
ROBERT RAPAPORT
Dr. Rapaport is Professor of Pediatrics and Chief of the Division of Pediatric Endocrinology and Diabetes as well as the Program Director for the Fellowship Program at the Icahn School of Medicine at Mount Sinai. He holds the Emma Elizabeth Sullivan Professor of Pediatric Endocrinology and Diabetes Chair at the Icahn School of Medicine at Mount Sinai.
Dr. Rapaport is a longtime member of the Pediatric Endocrine Society, Endocrine Society and the Growth Hormone Research Society and has served in various capacities in these organizations. He is an elected member of the American Pediatric Society. Dr. Rapaport is also active in both the American Diabetes Association and the Juvenile Diabetes Research Foundation. He has served on the editorial boards of the Journal of Clinical Endocrinology and Metabolism, the Journal of Pediatric Endocrinology & Metabolism, Pediatric Endocrinology Reviews, and other publications. Currently he serves as senior editor of Endocrine Connections, editor of the Journal of Diabetes, Advances in Neuroimmune Biology and others. He has published numerous peer-reviewed publications, chapters, reviews and more recently served as editor of several editions of Endocrinology and Metabolism Clinics of North America dedicated to Pediatric Endocrinology.
ALAN D. ROGOL, MD, PH.D
Professor, Emeritus
Department of Pediatrics
University of Virginia, Charlottesville, VA, USA
RON ROSENFELD, MD
Professor and Chair of Pediatrics (emeritus)
Oregon Health & Science University
President, STAT5, LLC
Portland (OR), USA
SILVERMAN, HOWARD
Professor, Clinical Informatics Fellowship
College of Medicine – Phoenix
The University of Arizona
Phoenix, AZ - USA
THORSTEN VON STEIN
Thorsten von Stein is a clinical development consultant to the biopharmaceutical industry, as well as the founder and president of Lapidary Scientific Computing, a company dedicated to bringing innovative software to medical and scientific communities.Over the past two decades, Dr. von Stein has served as chief medical officer of California-based biotechnology companies Tercica, NeurogesX and Zosano Pharma, and, before that, as clinical development leader at Hoffmann-La Roche in Basel, Switzerland, and Palo Alto, California. He has led the successful clinical development of drugs in osteoporosis, pain management and pediatric endocrinology.
Dr. von Stein received his medical degree from Munich University, Germany, and his Ph.D. in Computer Science from the University of Hamburg, Germany.
Programa
FIRST SESSION: Growth hormone and growth hormone deficiency-MODERATOR: Ron Rosenfeld
- 08:00 – 08:55 Registro
- 09:00 – 09:10 Palabras de bienvenida
Carlos Montúfar, PhD
Rector - Universidad San Francisco de Quito (USFQ), Ecuador - 09:15 – 09:50 Secreción y acción de la hormona del crecimiento (GH)
Introducción – (7 min) - (Vanessa Noboa)
Conferencia (23 min) – John Kopchick, PhD - Ohio University, USA
Q & A (5 min) - 09:55 – 10:30 Deficiencia de GH (GHD) debido a defectos hipotálamo-hipofisarios
Introducción (7 min) - (Andres Caicedo)
Conferencia (23 min) - Sally Radovick, The Child Health Institute, NJ, USA
Q & A (5 min) - 10:30 – 11:00 Coffee break
- 11:00 – 11:35 IUGR
Introducción (7 min) - (Enrique Teran)
Conferencia (23 min) – Robert Rapaport, NY, USA
Q & A (5 min) - 11:40 – 12:15 Diagnóstico y tratamiento de la GHD en niños
Introducción (7 min) - (Patricio Procel)
Conferencia (23 min) - Ignacio Bergada, Argentina
Q & A (5 min) - 12:20 – 12:55 Diagnóstico y tratamiento del GHD en adultos
Introducción (7 min) - (Gustavo Fierro)
Conferencia (23 min) – Andrew Hoffman, Stanford University, USA
Q & A (5 min - 12:55 – 14:20 Almuerzo
- 14:25 – 15:00 Pruebas de GH: ¿Qué pruebas y, primar o no primar?
Introducción (7 min) - (Luis Eguiguren)
Conferencia (23 min) – Alan Rogol, University of Virginia, USA
Q & A (5 min) - 15:05 – 15:40 Fisiología del IGF
Introducción (7 min) - (Enrique Teran)
Conferencia (23 min) – Jan Frystyk, Aarhus University, Denmark
Q & A (5 min) - 15:45 – 16:15 Coffee break
- 16:20 – 16:55 Bases moleculares de la resistencia a la GH y la deficiencia de IGF-I
Introducción (7 min) - (Caridad Davalos)
Conferencia (23 min) – Vivian Hwa, Cincinnati, USA
Q & A (5 min) - 17:00 – 17:40 El papel del clínico en la promoción de la resiliencia de los individuos y las familias con anomalías de crecimiento
Introducción (10 min) Michelle Grunauer, Dean of the College of Medicine USFQ
Conferencia (23 minutes) Howard Silverman, Professor of Medical Ethics & Humanism
College of Medicine, University of Arizona, Phoenix
SECOND SESSION: IGF-I, rhIGF-1 and IGF-I Deficiency-MODERATOR: Ron Rosenfeld
- 08:30 – 09:05 Consecuencias neurológicas de la deficiencia primaria de IGF-I por GHRD
Introducción (7 min) - (Francisco Fierro)
Conferencia (23 min) – Valter Longo, USC, USA
Q & A (5 min) - 09:10 – 09:45 Consecuencias cardiovasculares de la deficiencia primaria de IGF-I por GHRD
Introducción (7 min) - (Carolina Guevara)
Conferencia (23 min) – Marco Canepa, University of Genova
Q & A (5 min) - 09:50 – 10:25 Consecuencias metabólicas de la deficiencia primaria de IGF-I por GHRD
Introducción (7 min) - (Mónica Perez)
Conferencia (23 min) – Jaime Guevara-Aguirre, USFQ, Ecuador
Q & A (5 min) - 10:30 – 11:00 Coffee break
- 11:00 – 11:35 Aprobación del rhIGF por la FDA y la EMA
Introducción (7 min) - (Monica Tarapues)
Conferencia (23 min) – Thorsten von Stein, Consultant, Drug Development, USA
Q & A (5 min) - 11:40 – 12:15 Tratamiento con rhIGF-I de la IGFD primaria
Introducción (7 min) - (Jaime Guevara)
Conferencia (23 min) – Philipe Backeljauw, Cincinnati, USA
Q & A (5 min) - 12:15 – 13:40 Almuerzo
- 13:40 – 14:15 Tratamiento combinado de GH/IGF-I: ¿Existe una razón de ser?
Introducción (7 min) - (Speaker from Latin America or Ecuador)
Conferencia (23 min) – George Bright, Consulting, Pediatric Endocrine Trials, USA
Q & A (5 min) - 14:20 – 14:55 Posibles aplicaciones del rhIGF-I: síndromes de resistencia a la insulina
Introducción (7 min) - (Miguel Pasquel)
Conferencia (23 min) – Siri Greeley, The University of Chicago, USA
Q & A (5 min) - 14:55 – 15:25 Coffee Break
- 15:30 – 16:05 Aplicaciones potenciales del rhIGF-I: enfermedades óseas e IGF-1
Introducción (7 min) - (Marisol Bahamonde)
Conferencia (23 min) – Madhusmita Misra, Harvard University, USA
Q & A (5 min) - 16:10 – 16:55 Panel: "El futuro del rhIGF-I"
Moderador: Ron Rosenfeld, OHSU & Stanford University
Panelistas: Ponentes de la segunda sesión - 17:00 – 17:10 Observaciones finales
Michelle Grunauer, USFQ, Ecuador
Registro
1.- Tarifas de registro
Categoría * Tarifa de Registro
- Médicos $300.00
- Otros profesionales $100.00
- Estudiantes $50.00
2.- Pagos y Registro
Para pagos en efectivo y transferencias bancarias utilice estos datos:
Universidad San Francisco de Quito
RUC: 1791836154001
Dirección: Vía Interoceánica y Diego de Robles
Telefono: 2971700
Banco: Banco Bolivariano
Número de Cuenta: 1645003014
Swift Code: BBOLECEG500
Por favor enviar una copia escaneada de su comprobante de depósito o transferencia al correo mavelez@usfq.edu.ec indicando los nombres completos del participante y los datos para la emisión de la factura:
- Nombre:
- CI/RUC:
- Dirección:
- Teléfono:
- Correo electrónico:
Para pagos con tarjeta de crédito
Continue con el proceso de registro realizando su pago en línea
